Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET

Company Participants

Louise Wilkie - VP of IR and Corporate Communications

Sandy Macrae - Chief Executive Officer

Mark McClung - Chief Operating Officer

Prathyusha Duraibabu - Chief Financial Officer

Jason Fontenot - Chief Scientific Officer

Nathalie Dubois-Stringfellow - Chief Development Officer

Bettina Cockroft - Chief Medical Officer

Andy Ramelmeier - Head of Technical Operations

Conference Call Participants

Ritu Baral - Cowen

Yanan Zhu - Wells Fargo

Mary Kay - Bank of America Merrill Lynch

Ben Burnett - Stifel

Gena Wang - Barclays

Nicole Germino - Truist

Maury Raycroft - Jefferies

Operator

Good day, ladies and gentlemen, and thank you, for standing by. Welcome to the Sangamo Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions].

At this time, I would like to turn the conference over to Ms. Louise Wilkie. Ma'am, please begin.

Louise Wilkie

Thank you. Good afternoon. I'm Louise Wilkie, Sangamo's Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; Bettina Cockroft, Chief Medical Officer; and Andy Ramelmeier, Head of Technical Operations. Slides from our corporate presentation can be found at our Web site, sangamo.com under the Investors & Media section on the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to the therapeutic and commercial potential of our product candidates, the anticipated plans and time lines of Sangamo and our collaborators for initiating and conducting clinical trials, screening and dosing patients and presenting clinical data, advancements of our product candidates, advancements of preclinical programs to the clinic, our investment focus and the sufficiency of our resources, our 2022 financial guidance, upcoming catalysts and guidance and other statements that are not historical facts. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in today's press release, which is available on our Web site.